JAK1 and Alzheimer disease: This extends to topical applications as well, with ruxolitinib cream, a selective JAK1/JAK2 inhibitor, receiving the Food and Drug Administration (FDA) approval for the treatment of AD, and momelotinib, another JAK1/JAK2 inhibitor, demonstrating significant anti-inflammatory effects through topical application [79,80].